{
  "meta": {
    "title": "15_Hypolipidemic_Drugs",
    "url": "https://brainandscalpel.vercel.app/15-hypolipidemic-drugs-eea2447e.html",
    "scrapedAt": "2025-11-30T12:34:07.398Z"
  },
  "questions": [
    {
      "text": "A 58-year-old patient with coronary artery disease has a deranged lipid profile and is started on statins. Which enzyme does this drug act on?",
      "choices": [
        {
          "id": 1,
          "text": "Acyl coA synthase"
        },
        {
          "id": 2,
          "text": "Acyl coA reductase"
        },
        {
          "id": 3,
          "text": "HMG coA synthetase"
        },
        {
          "id": 4,
          "text": "HMG coA reductase"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Statins</strong> act on the <strong>HMG-CoA reductase</strong> enzyme, thus inhibiting cholesterol synthesis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c9ab5f58a5a14b499192aef0fe17276dx1280x788.JPEG\" alt=\"Explanation Image\"><p>Note:&nbsp;<span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Necrotizing myopathy is a newly defined form of idiopathic inflammatory myopathy. Patients who have anti-HMGCR antibodies and use of statin therapy to control high cholesterol may unknowingly develop this type of statin-induced necrotizing myopathy.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\"><strong>Necrotizing myopathy</strong> is a newly defined form of idiopathic inflammatory myopathy. Patients who have <strong>anti-HMG Co-A reductase antibodies </strong>should not be given&nbsp;statins to control high cholesterol as they may develop this type of <strong>statin-induced</strong> necrotizing myopathy.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2016",
      "difficulty": "easy"
    },
    {
      "text": "Hepatic cholesterol synthesis is maximal between midnight and 2 am. So most of the statins are preferably administered in the evening for maximal effect. Which statin can be taken irrespective of the time of the day?",
      "choices": [
        {
          "id": 1,
          "text": "Simvastatin"
        },
        {
          "id": 2,
          "text": "Pravastatin"
        },
        {
          "id": 3,
          "text": "Atorvastatin"
        },
        {
          "id": 4,
          "text": "Lovastatin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Atorvastatin </strong>has a longer half-life (19 ± 9 hours) and may be taken at<strong> any time of the day.</strong> </p>\n<p>Other drugs that can be taken irrespective of the time of day:</p>\n<ul>\n<li><strong>Rosuvastatin - </strong>has a half-life of 20 ± 6 hours</li>\n<li><strong>Pitavastatin</strong> - has a half-life of 12 hours </li>\n</ul>\n<p>All other statins, which have a plasma half-life of around 4 hours or less, should preferably be administered in the evening.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2964",
      "difficulty": "medium"
    },
    {
      "text": "A patient with hypercholesterolemia on statin therapy presents to your OPD for follow-up. You notice his cholesterol is still high and decide to add on another drug that directly inhibits the absorption of cholesterol. Which of the following will you prescribe?",
      "choices": [
        {
          "id": 1,
          "text": "Ezetimibe"
        },
        {
          "id": 2,
          "text": "Orlistat"
        },
        {
          "id": 3,
          "text": "Cholestyramine"
        },
        {
          "id": 4,
          "text": "Niacin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Ezetimibe </strong>is the drug that prevents hypercholesterolemia by directly<strong> inhibiting </strong>the<strong> absorption of cholesterol.</strong></p>\n<p>Ezetimibe acts by interfering with a specific cholesterol transport protein <strong>NPC1L1</strong> in the <strong>intestinal mucosa</strong> and reduces the absorption of both dietary and biliary cholesterol. It causes a&nbsp;compensatory increase in hepatic cholesterol synthesis but LDL cholesterol is decreased.&nbsp;<strong>Statins</strong> block this enhanced cholesterol synthesis (cholesterol synthesis inhibitors) and so their combination has a <strong>synergistic effect</strong>.</p>\n<p>Option B: <strong>Orlistat</strong> is an anti-obesity drug that acts by <strong>inhibiting pancreatic and gastric lipase</strong> and thus interferes with the digestion and absorption of dietary triglycerides.</p>\n<p>Option C: <strong>Cholestyramine</strong> is a <strong>bile acid sequestrant</strong>. The bile-acid sequestrants are highly positively charged and bind negatively charged bile acids. Because of their large size, the resins are not absorbed, and the bound bile acids are excreted in the stool.</p>\n<p>Cholestyramine primarily <strong>reduces LDL levels</strong> by <strong>increasing hepatic bile acid synthesis</strong>; which results in increased LDL uptake and diversion of cholesterol to bile acid production.&nbsp;</p>\n<p>Option D: <strong>Niacin</strong> reduces lipolysis by <strong>hormone-sensitive lipase</strong> (HSL) and reduces hepatic triglyceride synthesis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2020",
      "difficulty": "medium"
    },
    {
      "text": "Which drug decreases Lipoprotein(a)?",
      "choices": [
        {
          "id": 1,
          "text": "Fenofibrate"
        },
        {
          "id": 2,
          "text": "Niacin"
        },
        {
          "id": 3,
          "text": "Gemfibrozil"
        },
        {
          "id": 4,
          "text": "Colestipol"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The drug that decreases Lipoprotein(a) is <strong>niacin</strong>.</p>\n<p>Niacin is the only lipid-lowering agent that <strong>lowers lipoprotein(a)</strong> levels significantly. It also results in a&nbsp;<strong>decrease in LDL, VLDL,&nbsp;</strong>and<strong> triglycerides</strong> along with an <strong>increase in HDL</strong> cholesterol.</p>\n<p>The main adverse effect of niacin is cutaneous flushing and pruritus which can be controlled by pretreatment with aspirin. Niacin can also cause hepatotoxicity, GI toxicity, and hyperuricemia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2027",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs would you warn a patient taking statins against, due to the highest risk of myopathy?",
      "choices": [
        {
          "id": 1,
          "text": "Fenofibrate"
        },
        {
          "id": 2,
          "text": "Gemfibrozil"
        },
        {
          "id": 3,
          "text": "Colestipol"
        },
        {
          "id": 4,
          "text": "Niacin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Myopathy risk</strong> is <strong>highest</strong> when <strong>statins</strong> are used along <strong>with gemfibrozil.</strong></p>\n<p>Gemfibrozil is a fibrate that<strong> inhibits </strong>the<strong> uptake of statins</strong> into the hepatocytes and <strong>prevents</strong> its <strong>metabolism</strong>, thereby increasing its bioavailability. Thus, the risk of toxicity of statins increases.</p>\n<p>Other drugs interacting similarly with statins include:</p>\n<ul>\n<li>Cyclosporine</li>\n<li>Digoxin</li>\n<li>Warfarin</li>\n<li>Macrolide antibiotics</li>\n<li>Azole antifungals.</li>\n</ul>\n<p>Option A: Fenofibrate does not have much interaction with statins.</p>\n<p>Option C: Colestipol is a bile acid sequestrant and does not have much effect on statin metabolism.</p>\n<p>Option D: Niacin can also rarely increase the risk of <strong>statin-induced myopathy</strong> but the <strong>risk</strong> is much <strong>lower</strong> than that with gemfibrozil. So here gemfibrozil is the best answer.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2959",
      "difficulty": "medium"
    },
    {
      "text": "A patient who is on statin therapy asks about a new drug called evolocumab that his friend is taking for hyperlipidemia. What is the route of administration of this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Intramuscular"
        },
        {
          "id": 2,
          "text": "Intradermal"
        },
        {
          "id": 3,
          "text": "Subcutaneous"
        },
        {
          "id": 4,
          "text": "Intravenous"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Evolocumab </strong>is a <strong>PCSK-9 inhibitor </strong>that is&nbsp;administered as<strong>&nbsp;</strong>a <strong>subcutaneous</strong> injection.</p>\n<p>PCSK-9 is a<strong>&nbsp;</strong>protease that binds to the LDL receptors on the surface of hepatocyte and enhances the lysosomal degradation of the LDL receptor. This results in higher plasma LDL levels. inhibition of PCSK-9 results in a <strong>reduction of plasma LDL</strong> levels.&nbsp;</p>\n<p>Two approved PCSK-9 inhibitors are alirocumab and evolocumab.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3019",
      "difficulty": "medium"
    },
    {
      "text": "Which among the following is a microsomal triglyceride transfer protein inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Ticlopidine"
        },
        {
          "id": 2,
          "text": "Gugulipid"
        },
        {
          "id": 3,
          "text": "Lomitapide"
        },
        {
          "id": 4,
          "text": "Evinacumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Microsomal triglyceride transfer protein <strong>(MTP) inhibitor</strong>&nbsp;is<strong> lomitapide.</strong></p>\n<p>MTP adds triglycerides to nascent VLDL in the liver and to chylomicrons in the intestine. Its inhibition <strong>decreases VLDL secretion</strong> and thus decreases the accumulation of LDL in the plasma. It is approved for use in <strong>homozygous familial hypercholesterolemia</strong>.&nbsp;</p>\n<p>Options A: <strong>Ticlopidine</strong> is an <strong>antiplatelet</strong> agent.&nbsp;</p>\n<p>Option B: <strong>Gugulipid</strong> is a <strong>plant extract</strong> that is commonly used for hyperlipidemia but has very little/no evidence to support its use.</p>\n<p>Option D: <strong>Evinacumab</strong> is a recently approved&nbsp;angiopoietin-like 3 (<strong>ANGPTL3</strong>)&nbsp;<strong>inhibitor.</strong> It is indicated as an adjunct to other LDL-cholesterol lowering therapies for&nbsp;homozygous familial hypercholesterolemia in adults and pediatric patients aged 12 years and older.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2999",
      "difficulty": "medium"
    },
    {
      "text": "A patient with hereditary hyperlipoproteinemia is prescribed a fibrate. What is the mechanism of action of this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Increased lipolysis of triglycerides"
        },
        {
          "id": 2,
          "text": "Inhibit lipolysis in adipose tissues"
        },
        {
          "id": 3,
          "text": "Inhibit HMG CoA synthetase"
        },
        {
          "id": 4,
          "text": "Binds bile acids and bile salts in the intestine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Fibrates</strong>&nbsp;<strong>increase</strong> the lipoprotein lipase activity through <strong>PPAR-<span class=\"s1\">&alpha;</span></strong>&nbsp;and cause increased<strong> lipolysis</strong> <strong>of triglycerides</strong>.</p>\n<p>Lipoprotein lipase (LPL) is a key enzyme in the degradation of VLDL. Fibrates bind to PPAR alpha and cause <strong>stimulation</strong> of <strong>lipoprotein lipase</strong> enzyme. Increased LPL synthesis enhances the clearance of triglyceride-rich lipoproteins. Additionally, fibrates also <strong>stimulate fatty acid oxidation</strong> and <strong>reduce</strong> the expression of <strong>apo C-III</strong> (inhibitor of lipolysis).</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Class</strong></td>\n<td><strong>HMG- CoA reductase inhibitors (statins)</strong></td>\n<td><strong>Fibrates</strong></td>\n<td><strong>Niacin</strong></td>\n<td><strong>Bile acid-binding resins</strong></td>\n<td><strong>Ezetimibe</strong></td>\n</tr>\n<tr>\n<td>Important examples</td>\n<td>\n<p class=\"p1\">Lovastatin, atorvastatin, fluvastatin, pravastatin, simvastatin, rosuvastatin, pitavastatin</p>\n</td>\n<td>\n<p class=\"p1\">Gemfibrozil and fenofibrate</p>\n</td>\n<td>Niacin</td>\n<td>&nbsp;\n<p class=\"p1\">Colestipol, cholestyramine, colesevelam</p>\n</td>\n<td>Ezetimibe</td>\n</tr>\n<tr>\n<td>Mechanism of action</td>\n<td>\n<p class=\"p1\">Inhibits HMG-CoA reductase</p>\n</td>\n<td>\n<p class=\"p1\">PPAR-<span class=\"s1\">&alpha; mediated increased lipolysis</span></p>\n</td>\n<td>Decreases the production of VLDLs and decreases the catabolism of HDLs</td>\n<td>Binds to bile acids in the intestinal lumen and increases excretion. This results in increased conversion of hepatic cholesterol to bile acids, and reduction in hepatic cholesterol content.</td>\n<td>Inhibits intestinal sterol absorption</td>\n</tr>\n<tr>\n<td>Major effects on lipoprotein levels</td>\n<td>\n<p>Reduces LDL levels</p>\n</td>\n<td>\n<p>Reduces triglyceride levels</p>\n<p>A moderate increase in HDL levels</p>\n</td>\n<td>\n<p>Reduces triglycerides,&nbsp; LDL, and lipoprotein a levels</p>\n<p>Significant <strong>increase HDL</strong> levels</p>\n</td>\n<td>Reduces LDL levels&nbsp;</td>\n<td>\n<p>Reduces LDL cholesterol</p>\n<p>Minimal increase in HDL level</p>\n<p>Also decreases the absorption of phytosterols</p>\n</td>\n</tr>\n<tr>\n<td>Important side effects</td>\n<td><strong>Myopathy</strong>\n<p class=\"p1\">Elevations of serum aminotransferase activity</p>\n<p class=\"p1\">Elevation of creatine kinase activity</p>\n</td>\n<td>\n<p class=\"p1\">Rashes, gastrointestinal symptoms, myopathy, arrhythmias</p>\n<p class=\"p1\">Hypokalemia, elevated aminotransferases, or alkaline phosphatase&nbsp;</p>\n</td>\n<td>\n<p>Cutaneous vasodilation</p>\n<p>Elevations in aminotransferases levels&nbsp;</p>\n</td>\n<td>\n<p>Constipation</p>\n<p>Bloating&nbsp;</p>\n</td>\n<td>\n<p>Reversible hepatic function impairment</p>\n<p>Rarely myositis</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2014",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old obese man presented to your OPD. His lipid profile showed elevated levels of cholesterol and triglycerides. On examination, you notice palmar xanthomas. What is the drug of choice for his condition?",
      "choices": [
        {
          "id": 1,
          "text": "Statins"
        },
        {
          "id": 2,
          "text": "Niacin"
        },
        {
          "id": 3,
          "text": "Fibrates"
        },
        {
          "id": 4,
          "text": "Alirocumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given scenario of elevated cholesterol and triglycerides along with the presence of <strong>palmar xanthomas</strong> (pathognomonic sign) is indicative of <strong>type III&nbsp;hyperlipoproteinemia. </strong>The drugs of choice for this condition are<strong>&nbsp;fibrates.</strong></p>\n<p>Fibrates are also preferred in patients having severe hypertriglyceridemia (TG &gt;1000 mg/dl) who are at risk for pancreatitis.&nbsp;</p>\n<p>The response to fibrate therapy in Type III&nbsp;hyperlipoproteinemia patients include:</p>\n<ul>\n<li>Elevated cholesterol and triglyceride levels are dramatically lowered.</li>\n<li>Tuberoeruptive and palmar xanthomas may regress completely.</li>\n<li>Angina and intermittent claudication also improve.&nbsp;&nbsp;</li>\n</ul>\n<p>The image below shows <strong>palmar xanthoma</strong>.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4b41419073a741deb611315c1b643f21x1280x1144.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Familial Dyslipidemias</h3><table>\n<tbody>\n<tr>\n<td>Type</td>\n<td>Increased levels&nbsp;</td>\n<td>Manifestation</td>\n</tr>\n<tr>\n<td>1. Hyperchylomicronemia(type I hyperlipoproteinemia)</td>\n<td>Chylomicrons, VLDL, TG&nbsp;</td>\n<td>Pancreatitis, hepatosplenomegaly, and xanthomas</td>\n</tr>\n<tr>\n<td>2.&nbsp;Familial hypercholesterolemia(type II&nbsp;hyperlipoproteinemia)</td>\n<td>LDL and cholesterol</td>\n<td>Atherosclerosis and xanthomas</td>\n</tr>\n<tr>\n<td>3. Dysbetalipoproteinemia(type III hyperlipoproteinemia)</td>\n<td>Chylomicrons and VLDL</td>\n<td>Atherosclerosis and xanthomas</td>\n</tr>\n<tr>\n<td>4. Hypertriglyceridemia(type IV hyperlipoproteinemia)</td>\n<td>VLDL and TG</td>\n<td>Pancreatitis</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2982",
      "difficulty": "medium"
    },
    {
      "text": "What is the drug of choice for type IIa and IIb hyperlipoproteinemias?",
      "choices": [
        {
          "id": 1,
          "text": "Statins"
        },
        {
          "id": 2,
          "text": "Fibrates"
        },
        {
          "id": 3,
          "text": "Niacin"
        },
        {
          "id": 4,
          "text": "Bile acid sequestrants"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The drugs of choice for <strong>type IIa and IIb hyperlipoproteinemias</strong> are <strong>statins</strong>.&nbsp;</p>\n<p>In type IIa or IIb hyperlipoproteinemias, there is increased LDL cholesterol with +/- increase in TG.&nbsp; Statins have the <strong>maximum LDL lowering</strong> property among the hypolipidemic drugs. Therefore, they are the drugs of choice in this case.</p>\n<p>In <strong>type III/IV hyperlipoproteinemias,&nbsp;</strong>there is mainly an increase in triglyceride(TG) level<strong>. Fibrates</strong> reduce the TGs contained in VLDL and increase the HDL. So they are the drugs of choice for these conditions.</p><hr><h3>Related Pearl: Familial Dyslipidemias</h3><table>\n<tbody>\n<tr>\n<td>Type</td>\n<td>Increased levels&nbsp;</td>\n<td>Manifestation</td>\n</tr>\n<tr>\n<td>1. Hyperchylomicronemia(type I hyperlipoproteinemia)</td>\n<td>Chylomicrons, VLDL, TG&nbsp;</td>\n<td>Pancreatitis, hepatosplenomegaly, and xanthomas</td>\n</tr>\n<tr>\n<td>2.&nbsp;Familial hypercholesterolemia(type II&nbsp;hyperlipoproteinemia)</td>\n<td>LDL and cholesterol</td>\n<td>Atherosclerosis and xanthomas</td>\n</tr>\n<tr>\n<td>3. Dysbetalipoproteinemia(type III hyperlipoproteinemia)</td>\n<td>Chylomicrons and VLDL</td>\n<td>Atherosclerosis and xanthomas</td>\n</tr>\n<tr>\n<td>4. Hypertriglyceridemia(type IV hyperlipoproteinemia)</td>\n<td>VLDL and TG</td>\n<td>Pancreatitis</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA2034",
      "difficulty": "medium"
    },
    {
      "text": "A patient with homozygous familial hypercholesterolemia has mipomersen as part of his treatment regimen. By which of the following mechanisms does this drug act?",
      "choices": [
        {
          "id": 1,
          "text": "Inhibition of microsomal triglyceride transfer"
        },
        {
          "id": 2,
          "text": "Inhibition of PCSK9"
        },
        {
          "id": 3,
          "text": "Inhibition of apo B-100 synthesis"
        },
        {
          "id": 4,
          "text": "Inhibition of cholesterol absorption"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Mipomersen is an&nbsp;<strong>antisense oligonucleotide </strong>that acts as an&nbsp;<strong>inhibitor</strong> of<strong> apo B-100 synthesis.&nbsp;</strong></p>\n<p>Mipomersen binds to the mRNA of apo B-100 resulting in degradation of apo B-100 mRNA and eventually reduction of apo B-100 synthesis.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3017",
      "difficulty": "medium"
    }
  ]
}